What the named product contains

Ziana is labeled as clindamycin phosphate 1.2% and tretinoin 0.025% gel. The label explains that each gram contains 10 mg of clindamycin, expressed as clindamycin base, and 0.25 mg of tretinoin. The two ways of describing clindamycin refer to the salt and the equivalent active base; they are not evidence of an inconsistent prescription. A pharmacist can clarify those expressions on an actual dispensing label.

The listed presentation is a topical gel in 30- and 60-gram tubes. Those quantities do not establish how many months a particular person’s prescription will last. The application area and instructions remain part of the prescription. Our prescription label guide explains why strength, package quantity and directions should be recorded separately.

Inactive ingredients include glycerin, carbomer, preservatives and other formulation components. A gel is not automatically suitable for every oily or sensitive complexion. Someone with a known ingredient allergy needs the complete current ingredient list, not a shortcut based on the word gel or an assumption that a lower tretinoin percentage guarantees comfort.

The approved purpose is acne

The Ziana label specifies topical treatment of acne vulgaris in patients age 12 or older. It does not establish a wrinkle treatment indication. A person seeking improvement in fine lines should not infer that an antibiotic belongs in that plan because both acne products and photoaging products can contain tretinoin.

The distinction also prevents an unfair product ranking. Our acne versus photoaging explanation separates the condition being treated from the ingredient name. Choosing an acne product and evaluating a cosmetic concern are different clinical decisions, even when the website search began with the same word.

For readers comparing prescription routes, Altreno’s lotion label offers another acne-specific example with a different formulation. These records support checking indications and formulations; they do not provide a head-to-head trial between every product in this publication.

What the trial record can establish

The prescribing information describes controlled studies of the specified Ziana formulation in acne and includes comparisons with components formulated in the study vehicle and with vehicle alone. That is more precise evidence than an ingredient-level marketing statement. It is still evidence from a defined population, treatment period and outcome assessment.

A reader should distinguish a change in lesion counts from a measure of overall treatment success. Neither measure can be converted into a promise that a particular person’s face will be clear by a particular date. The studies also do not establish that this gel is superior to an unrelated compounded blend sold online or that its results apply to sun damage.

The label describes clinical-study limitations for adverse-event comparisons, too. People in different trials may have different baseline skin conditions and monitoring. Comparing percentages across separate product labels as though the participants were randomized together would create a misleading safety league table. We therefore do not assign a clinical performance score from those numbers.

Clindamycin changes the safety conversation

Ziana is contraindicated in people with regional enteritis, ulcerative colitis or a history of antibiotic-associated colitis. The label also warns that systemic absorption of topical clindamycin occurs and that diarrhea, bloody diarrhea and colitis have been reported. The fact that a medicine goes on the skin does not erase the relevance of gastrointestinal history.

The prescribing information directs discontinuation when significant diarrhea occurs. Someone experiencing significant diarrhea or bloody stools while using this medicine should contact the prescribing clinician promptly and seek urgent assessment for severe symptoms. This is not a situation to dismiss as ordinary skin adjustment or to manage by changing the amount of gel without medical advice.

Skin redness, scaling, itching, burning and stinging are also described. The record cautions about other topical products with irritating or drying effects. Pregnancy, breastfeeding, other medicines and prior reactions need discussion with the care team. Our pregnancy and breastfeeding guide explains why a general online article cannot determine suitability.

Antibiotic follow-up is part of the review

Tretinoin is a retinoid, not an antibiotic. Clindamycin is the antibiotic component in Ziana. The AAD’s 2024 acne guideline summary recommends antibiotic stewardship and using benzoyl peroxide alongside topical or oral antibiotics to reduce resistance. That guidance creates a question for the prescriber about the complete treatment plan; it is not an instruction to add another product independently.

Product compatibility, irritation and the existing prescription still matter. Ask the clinician how the antibiotic component will be reviewed, which other treatments belong in the plan and what should happen when the next prescription is due. Our guide to antibiotic-containing formulas develops those questions without supplying a personal schedule.

A refill reminder from a pharmacy is an administrative event. It is not proof that an antibiotic-containing treatment should continue unchanged indefinitely. Equally, an article about resistance is not a reason to abruptly replace a clinician’s plan. The useful action is a documented review of response, tolerability and the continuing reason for each ingredient.

Cost and availability remain separate questions

DailyMed is a labeling resource, not a live inventory or insurance quotation. This review does not establish that every pharmacy stocks the branded product, that a generic substitution will be offered, or that a particular insurance plan will cover it. Request a written quotation identifying the exact drug, package size, manufacturer when relevant and any consultation charge.

For a proposed substitution, ask the pharmacist what is being substituted and what information accompanies it. A compounded preparation with some of the same ingredients does not automatically acquire the approval, formulation evidence or labeling of Ziana. FDA states that compounded medicines are not reviewed for safety, effectiveness and quality before marketing in the way approved drugs are.

The CoreAge Rx review concerns a separately advertised compounded tretinoin, niacinamide and vitamin C product. It should be read on its own terms. A complete comparison begins with the condition being addressed, the exact formula and the clinician’s reasoning—not with a sponsored position or a shared ingredient.